Tweetovi

Blokirali ste korisnika/cu @CRISPRTX

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CRISPRTX

  1. 14. sij

    Congratulations to our co-founder Emmanuelle Charpentier and professor Jennifer Doudna on winning the 2020 Wolf Prize in Medicine for their pioneering work in CRISPR-Cas9 gene-editing technology! Learn more here:

    Poništi
  2. 10. pro 2019.

    And is a wrap! Team had a great time connecting with colleagues, peers, and industry leaders. Thanks for a great conference and thanks to everyone who came by our booth!

    Poništi
  3. 19. stu 2019.

    and announce early positive safety and efficacy data from the first two patients treated with the investigational CRISPR/Cas9 gene-editing therapy CTX001 for severe hemoglobinopathies. Learn more here:

    Poništi
  4. 9. stu 2019.

    Several proud members of team highlighting data at ! We’re moving at a rapid pace, and every day presents new excitements and challenges. Want to be a part of our groundbreaking team? Learn more here:

    Poništi
  5. 8. stu 2019.

    At ? Stop by our poster (). We’ll be highlighting data related to single-cell RNA sequencing and functional assessment of healthy donor and cancer patient-derived T and CAR-T cells.

    Poništi
  6. 1. stu 2019.

    We were thrilled to host our 2019 Volunteer Day this week in partnership with and , making over 80 blankets, 40 Happy Hope Bags and sorting donated clothing, impacting over 1,000 children in the Greater Boston area. Thanks to all of our employees!

    Poništi
  7. 28. lis 2019.

    provides business update and reports Q3 2019 financial results. Learn more in our press release:

    Poništi
  8. 21. lis 2019.

    Today and Bayer shared an update on Casebia Therapeutics. Learn more in the press release:

    Poništi
  9. 16. lis 2019.

    We were excited to meet those in the community last week ’s Annual National Convention where our Head of R&D Tony Ho spoke about our efforts to advance treatments for SCD

    Poništi
  10. 15. lis 2019.

    and announce license agreement to advance companies’ respective cell therapy programs in oncology. Learn more here:

    Poništi
  11. 24. ruj 2019.

    The has issued a new patent to the Charpentier/Doudna teams, covering new compositions and methods. Learn more here:

    Poništi
  12. 18. ruj 2019.

    The has issued a new patent to the Charpentier/Doudna teams, covering single-molecule guide RNA compositions and other methods. Learn more here:

    Poništi
  13. 17. ruj 2019.

    Today, and presented data on a regenerative medicine program targeted towards type 1 diabetes at showing successful differentiation of CRISPR-edited human pluripotent stem cells to pancreatic precursor cells. Learn more here:

    Poništi
  14. 16. ruj 2019.

    The team had an amazing day at the annual walk for . Thanks to all the supporters who joined us to raise awareness.

    Poništi
  15. 11. ruj 2019.

    Excited to have been part of the where our Head of Hemoglobinopathies Programs Krista McKerracher spoke on our approach to treating . Learn more about our work here:

    Poništi
  16. 10. ruj 2019.

    The has granted a new patent to the Charpentier/Doudna teams related to single-guide RNAs. Learn more here:

    Poništi
  17. 29. srp 2019.

    provides business update and reports Q2 2019 financial results. Learn more in our press release:

    Poništi
  18. 23. srp 2019.

    The has issued two new patents to the Charpentier/Doudna teams that cover methods of targeting and binding, modifying or cleaving a target DNA. Learn more here:

    Poništi
  19. 19. srp 2019.

    Team spent the afternoon at Fenway Park cheering on the Red Sox to a win!

    Poništi
  20. 16. srp 2019.

    The has issued a new patent to the Charpentier/Doudna teams which involves introducing Cas9 into a cell for genome editing. Learn more here:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·